Table 1 Patients characteristics
Characteristics | BM group | Non-BM group | P | Total |
|---|---|---|---|---|
No. (%) | No. (%) | No. (%) | ||
Age | ||||
 < 60 | 20 (14.8%) | 22 (16.3%) | 0.225 | 42 (31.1%) |
 ≥ 60 | 34 (25.2%) | 59 (43.7%) |  | 93 (68.9%) |
Sex | ||||
 Male | 26 (19.3%) | 32 (23.7%) | 0.320 | 58 (43.0%) |
 Female | 28 (20.7%) | 49 (36.3%) |  | 77 (57.0%) |
Smoking history | ||||
 Yes | 18 (13.4%) | 28 (20.7%) | 0.882 | 46 (34.1%) |
 No | 36 (26.7%) | 53 (39.2%) |  | 89 (65.9%) |
EGFR mutation | ||||
 19 del | 30 (22.2%) | 53 (39.3%) | 0.248 | 83 (61.5%) |
 21 L858R | 24 (17.8%) | 28 (20.7%) |  | 52 (38.5%) |
ECOG-PS | ||||
 0–1 | 48 (35.6%) | 75 (55.6%) | 0.459 | 123 (91.2%) |
 2–3 | 6 (4.4%) | 6 (4.4%) |  | 12 (8.8%) |
Type of BMa | ||||
 Osimertinib after BM | 33 (61.1%) | – |  | 33 (61.1%) |
 Osimertinib before BM | 21 (38.9%) | – |  | 21 (38.9%) |
Size of the largest BM (cm)a | ||||
 < 1 | 38 (70.4%) | – |  | 38 (70.4%) |
 ≥ 1 | 16 (29.6%) | – |  | 16 (29.6%) |
 Number of BMa | ||||
 ≤ 3 | 14 (25.9%) | – |  | 14 (25.9%) |
 > 3 | 40 (74.1%) | – |  | 40 (74.1%) |
Symptom of BMa | ||||
 Yes | 12 (22.2%) | – |  | 12 (22.2%) |
 No | 42 (77.8%) | – |  | 42 (77.8%) |
DS-GPAa | ||||
 0–1.5 | 15 (27.8%) | – |  | 15 (27.8%) |
 2–4 | 39 (72.2%) | – |  | 39 (72.2%) |
Radiotherapy (BM)a | ||||
 WBRT/SRS | 37 (68.5%) | – |  | 37 (68.5%) |
 No | 17 (31.5%) | – |  | 17 (31.5%) |